<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02035852</url>
  </required_header>
  <id_info>
    <org_study_id>STU 062010-160</org_study_id>
    <secondary_id>1R01CA154843-01A1</secondary_id>
    <nct_id>NCT02035852</nct_id>
  </id_info>
  <brief_title>High Resolution Magnetic Resonance Imaging in Patients With Brain Tumors</brief_title>
  <official_title>High Resolution Magnetic Resonance Imaging in Patients With Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare two different size MRI's of a brain tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to directly compare the MR images of a brain tumor obtained on the 3T&#xD;
      and then 7T MRI in approximately 150 patients followed serially with MR imaging to evaluate&#xD;
      for tumor progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 28, 2009</start_date>
  <completion_date type="Actual">April 20, 2018</completion_date>
  <primary_completion_date type="Actual">April 19, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Benefit of 7T MR imaging</measure>
    <time_frame>Baseline and 6 month intervals after baseline</time_frame>
    <description>1. To determine the benefit of 7T MR imaging in brain tumor patients with regard to the improvement in resolution, as measured by the area of T2 FLAIR signal abnormality and the ability to detect abnormalities in vascular integrity. The benefit will be determined at a single time point as well as longitudinally for each patient at 6 month intervals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vascular Integrity</measure>
    <time_frame>Every 6 months, up to 12 months.</time_frame>
    <description>To determine if changes in vascular integrity at 7T can be correlated with tumor progression or transformation to high grade in patients with low grade gliomas.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">184</enrollment>
  <condition>Brain Tumor</condition>
  <arm_group>
    <arm_group_label>Adult Gilomas</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>3T MRI vs. 7T MRI</description>
    <arm_group_label>Adult Gilomas</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients at the Simmons Cancer Center at UTSW&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, age 18 years or older&#xD;
&#xD;
          -  Patient must meet at least one of the four following criteria regarding brain tumor&#xD;
             diagnosis:&#xD;
&#xD;
          -  Histological diagnosis of a brain tumor&#xD;
&#xD;
          -  Histological diagnosis of systemic cancer and brain MR imaging suggestive of&#xD;
             metastatic disease to the brain&#xD;
&#xD;
          -  Pre-operative brain MR imaging suggestive of a brain tumor&#xD;
&#xD;
          -  Radiographic diagnosis of brain tumor in an inoperable location (e.g., brainstem)&#xD;
&#xD;
          -  Patient able and willing to provide informed consent&#xD;
&#xD;
          -  Karnofsky Performance status &gt; 70%&#xD;
&#xD;
          -  Life expectancy greater than 3 months&#xD;
&#xD;
          -  Negative serum or urine pregnancy test or child bearing potential terminated by&#xD;
             surgery, radiation, menopause or current use of two approved methods of birth control&#xD;
&#xD;
          -  Patients who are excluded from 7T MR imaging because of titanium implants that are not&#xD;
             yet established to be safe at 7T remain eligible for the imaging at 3T * Spanish&#xD;
             speaking participants will be enrolled for this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body weight &gt;137 Kg (300 lbs)&#xD;
&#xD;
          -  Patient unable to provide informed consent&#xD;
&#xD;
          -  Karnofsky Performance status &lt; 70%&#xD;
&#xD;
          -  Patients who are claustrophobic or have other contraindications to MRI, such as&#xD;
             implanted pacemaker device vascular clips, surgical clips, prosthetic valves,&#xD;
             pacemakers, otologic implants&#xD;
&#xD;
          -  NYHA class III and IV congestive heart failure&#xD;
&#xD;
          -  Psychiatric or addictive disorders that preclude obtaining informed consent&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  Sexually active patients of childbearing potential not using a reliable contraceptive&#xD;
             method&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Women of childbearing potential who refuse a pregnancy test (performed during&#xD;
             screening)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Maher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>June 12, 2012</study_first_submitted>
  <study_first_submitted_qc>January 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2014</study_first_posted>
  <last_update_submitted>December 28, 2018</last_update_submitted>
  <last_update_submitted_qc>December 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

